Coya Therapeutics is expanding the pipeline for its COYA 302 immunotherapy, adding two neurodegenerative disorders — frontotemporal dementia (FTD)…
Articles by Patricia Inácio, PhD
Scientists have developed a molecule that promotes the clearance of toxic clumps of the alpha-synuclein protein — a hallmark of…
The U.S. Food and Drug Administration (FDA) has given Zydus Lifesciences a green light to conduct a Phase 2 trial…
Neurocrine Biosciences is opening two Phase 1 clinical trials in healthy adults to test two oral candidate muscarinic…
Members of the Support Group for Black Patients with Parkinson’s Disease took part in the Parkinson Council’s Walk to…
Two leading nonprofit institutes have launched the GA4GH & INCF Neuroscience Community to better connect researchers around the world studying…
The Institute for Glial Sciences, a center dedicated to the role of glial cells in Parkinson’s disease and others…
An ongoing and global Phase 3 clinical trial program for oral tavapadon, a selective dopamine receptor agonist…
Enrollment is now complete for a Phase 2 trial that’s assessing the safety and efficacy of oral vodobatinib (K0706), an…
A trial investigating the feasibility and impact of a novel approach for increasing regular exercise among Hispanic people with…